Next-Generation Bispecific Nanobody Targeting ANGPT2 and DLL4 for Cancer Therapy

VHH-P764 is a humanized bispecific nanobody engineered to target angiopoietin 2 (ANGPT2) and delta like canonical Notch ligand 4 (DLL4). Currently in the Biological Testing development stage, VHH-P764 offers a novel therapeutic approach for cancer. By simultaneously focusing on ANGPT2 and DLL4, both of which are critical regulators in tumor angiogenesis and progression, this bispecific construct aims to address the complex biology of cancer vascularization. The unique structure of VHH-P764 enables it to bind efficiently to its dual targets, paving the way for a potentially effective and innovative therapy for malignant conditions.

Licensing Opportunity

VHH-P764 is available for out-licensing and strategic partnership opportunities. We welcome inquiries from organizations interested in collaborating on the further development and commercialization of this innovative bispecific nanobody therapy for cancer.

Development Phase

Modality

VHH-P764 utilizes a bispecific single-domain antibody (nanobody) modality, constructed from heavy chain variable domains that independently bind both ANGPT2 and DLL4. The design integrates both binding domains with a flexible 9-mer Gly-Ser linker and further couples them to an anti-human serum albumin moiety, enhancing systemic half-life. The small molecular size and single-domain nature of nanobodies result in superior tissue penetration and robust stability, attributes particularly beneficial for reaching tumor vasculature in solid tumors. This advanced structure positions VHH-P764 to overcome delivery barriers, providing greater therapeutic exposure and potential synergy in cancer treatment.

Target

ANGPT2 and DLL4 are well-established molecular targets implicated in cancer progression. ANGPT2 is a key regulator of angiogenesis, predominantly expressed in vascular endothelial cells within tumors, where it mediates vascular remodeling and destabilization. DLL4, a ligand in the Notch signaling pathway, is also primarily expressed in endothelial cells and is essential for vascular sprouting and maturation. Targeting ANGPT2 and DLL4 disrupts tumor neovascularization and impairs the tumor's adaptive mechanisms. The dual engagement by VHH-P764, targeting both ANGPT2 and DLL4, is strategically valuable—simultaneously addressing two complementary pathways in tumor angiogenesis, which enhances the blockade of compensatory vascular mechanisms and potentially limits resistance. This bispecific approach offers a promising pathway for innovative cancer therapeutics.

Mechanism of Action

VHH-P764 is designed as a signal transduction modulator by selectively binding to both ANGPT2 and DLL4 on tumor-associated endothelial cells. By blocking ANGPT2, VHH-P764 inhibits angiogenic signaling that promotes tumor vascular destabilization and growth. Concurrently, interference with DLL4 disrupts the Notch pathway, further inhibiting abnormal vessel formation and supporting normalization of the tumor microenvironment. This dual blockade of ANGPT2 and DLL4 may synergistically impair tumor angiogenesis, limiting nutrient supply and metastatic potential. The nanobody platform offers additional versatility, supporting future development as antibody-drug conjugates or multi-specific therapeutics, thus broadening applications across diverse cancer types.

Cancer

Cancer remains a leading cause of mortality worldwide, affecting millions of individuals each year across all age groups and geographic regions. Tumor development is characterized by uncontrolled cell proliferation, invasion of surrounding tissues, and, frequently, the formation of new blood vessels (angiogenesis) that supply nutrients for tumor growth and metastasis. Presently, treatment modalities include surgery, radiation, chemotherapy, immunotherapy, and targeted biological agents. However, resistance, limited specificity, toxicity, and incomplete efficacy underline the ongoing need for innovative therapies. Angiogenesis is a pivotal process in cancer progression, and current anti-angiogenic agents demonstrate variable success and evolving resistance mechanisms. VHH-P764, with its bispecific targeting of angiogenesis regulators ANGPT2 and DLL4, offers a promising opportunity to disrupt tumor vascularization and address unmet needs in the oncology landscape, potentially improving outcomes for patients with resistant or advanced disease.